Michael J Hadd

Title: Michael J Hadd: Innovator in Pharmaceutical Formulations

Introduction

Michael J Hadd is a notable inventor based in San Jose, CA. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of extended release tablets for SGLT2 inhibitors. His innovative approach aims to enhance the pharmacokinetic profile of medications, providing better therapeutic outcomes for patients.

Latest Patents

Michael J Hadd holds a patent for pharmaceutical formulations that improve the pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin. His patent describes how formulating this medication as an extended release tablet can lower peak plasma concentrations while maintaining therapeutic levels over a desired period. This advancement allows for the administration of lower doses without compromising the pharmacological effect, which can be crucial for patient care.

Career Highlights

Hadd's career is marked by his work at Theracosbio, LLC, where he has been instrumental in developing innovative pharmaceutical solutions. His expertise in drug formulation has positioned him as a key player in the industry, contributing to advancements that benefit both healthcare providers and patients.

Collaborations

Michael J Hadd collaborates with talented professionals in his field, including Brian Seed and Feng Wang. These partnerships enhance the research and development efforts at Theracosbio, LLC, fostering an environment of innovation and excellence.

Conclusion

Michael J Hadd's contributions to pharmaceutical formulations exemplify the impact of innovation in healthcare. His work not only advances drug delivery systems but also improves patient outcomes through more effective medication management.